Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.43 |
| ▸ | SKP1 | P63208 | 2/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719295 | 0.86 | USP30 (0.44) | USP30GPR119CKS1BSKP1SKP2 | |
| SCHEMBL14719212 | 0.83 | SCD5 (0.43) | USP30GPR119CKS1BSKP1SKP2 | |
| SCHEMBL1751366 | 0.81 | GPR119 (0.45) | USP30GPR119CKS1BSKP1SKP2 | |
| SCHEMBL14719326 | 0.77 | USP30 (0.40) | USP30GPR119CKS1BSKP1SKP2 | |
| SCHEMBL31080015 | 0.75 | USP2 (0.50) | GPR119MAPK1NR1H2KDM4E | |
| SCHEMBL1751873 | 0.75 | ESR2 (0.48) | USP30GPR119CKS1BSKP1SKP2 | |
| SCHEMBL1751837 | 0.74 | CHRM5 (0.53) | CKS1BSKP1SKP2 | |
| SCHEMBL17369314 | 0.73 | MAPK1 (0.54) | GPR119MAPK1NR1H2NAMPT | |
| SCHEMBL29813840 | 0.73 | MAPK1 (0.54) | GPR119MAPK1NR1H2NAMPT | |
| SCHEMBL16049290 | 0.73 | ESR2 (0.46) | USP30GPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053565-A1 | SUBSTITUTED 3-PIPERIDONE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053565-A1 | SUBSTITUTED 3-PIPERIDONE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053565-A1 | SUBSTITUTED 3-PIPERIDONE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053565-A1 | SUBSTITUTED 3-PIPERIDONE COMPOUNDS | HTR3C, NPEPPS, RAP2C | USP30 3130/4885GPR119 1675/4885CKS1B 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.